Chemomab Therapeutics (CMMB) Expected to Announce Quarterly Earnings on Wednesday

Chemomab Therapeutics (NASDAQ:CMMB) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). On average, analysts expect Chemomab Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Stock Up 3.4%

Shares of NASDAQ CMMB opened at $1.83 on Tuesday. The firm has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.97. The stock has a market capitalization of $13.16 million, a price-to-earnings ratio of -0.71 and a beta of 0.51. Chemomab Therapeutics has a 52 week low of $1.35 and a 52 week high of $5.88.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.00.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd purchased a new stake in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned about 0.31% of Chemomab Therapeutics as of its most recent SEC filing. 46.05% of the stock is currently owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.